The present application belongs to the field of chemical
medicine, and particularly relates to a combined
drug for preventing and / or treating
prostate cancer, use and pharmaceutical composition thereof. The combined
drug of the present application is an immune
cell with enhanced infiltration degree and a
galectin-1 inhibitor; the immune
cell with enhanced infiltration degree is a natural killer (NK)
cell with TTTY15-USP9Y chimera
RNA knocked out, which can increase the infiltration degree and anti-tumor activity of the NK cell in the
prostate cancer microenvironment, and the activated NK cell has stronger killing effect on
tumor cells in vitro. The present application combines the immune cell with enhanced infiltration degree and the
galectin-1 inhibitor, and the combination shows synergistic effect in treating
prostate cancer, and has wide application prospect.